hkatie
Networker
Commercial insurance audit activity in my area has prompted some worried questions from a few of my providers. Although we are very clear on benign lesion removal policies with respect to medical necessity, one commercial carrier may be toughening up on supporting the medical necessity of skin biopsies. "Suspected malignancy" is a common term I see in policies, but I'm hoping some of you would share some of the descriptions you typically see in your provider's documentation that seem to support the medical necessity of performing a biopsy. For instance, if you see a provider's description of a lesion as "red lesion that crusts, heals, and crusts again" would that be enough or do your providers typically add more robust descriptions that include statements about pearly telangiectic papules that bleed and crust? (I'm thinking r/o bcc here.) Of course our providers don't add in descriptions they don't find on exam, but I think we all know that sometimes they provide bare minimum details, especially on those days when they have too many add-ons on their schedules. Thanks in advance for sharing your thoughts.